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Background. Morbidity and mortality for critically ill patients with infections remains a global healthcare prob-
lem. We aimed to determine whether β-lactam antibiotic dosing in critically ill patients achieves concentrations as-
sociated with maximal activity and whether antibiotic concentrations affect patient outcome.
Methods. This was a prospective, multinational pharmacokinetic point-prevalence study including 8 β-lactam
antibiotics. Two blood samples were taken from each patient during a single dosing interval. The primary pharma-
cokinetic/pharmacodynamic targets were free antibiotic concentrations above the minimum inhibitory concentra-
tion (MIC) of the pathogen at both 50% (50% f T>MIC) and 100% (100% f T>MIC) of the dosing interval. We used
skewed logistic regression to describe the effect of antibiotic exposure on patient outcome.
Results. We included 384 patients (361 evaluable patients) across 68 hospitals. The median age was 61 (inter-
quartile range [IQR], 48–73) years, the median Acute Physiology and Chronic Health Evaluation II score was 18
(IQR, 14–24), and 65% of patients were male. Of the 248 patients treated for infection, 16% did not achieve 50%
f T>MIC and these patients were 32% less likely to have a positive clinical outcome (odds ratio [OR], 0.68;
P = .009). Positive clinical outcome was associated with increasing 50% f T>MIC and 100% f T>MIC ratios (OR,
1.02 and 1.56, respectively; P < .03), with signiﬁcant interaction with sickness severity status.
Conclusions. Infected critically ill patients may have adverse outcomes as a result of inadeqaute antibiotic ex-
posure; a paradigm change to more personalized antibiotic dosing may be necessary to improve outcomes for these
most seriously ill patients.
Keywords. continuous infusion; extended infusion; adverse events; pharmacokinetics; pharmacodynamics.
Infections in critically ill patients are a major burden to
the healthcare system. Of concern for clinicians and
administrators, neither the incidence of these infections
over the past 30 years nor the mortality rates appear to
be improving. This challenging dilemma has led to 70%
of all intensive care unit (ICU) patients being
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prescribed antibiotics at any one time [1]. With such high rates
of usage, it is easy to understand why the ICU stay is associated
with the development of increasing levels of antibiotic-resistant
bacteria that then pervade other healthcare settings.
For severe infections causing sepsis and septic shock, the
early initiation of antibiotics with an appropriate spectrum
for the likely pathogen has been demonstrated to be an effective
intervention [2–4]. It has been suggested that superior infection
outcomes could be achieved in critically ill patients by optimi-
zation of the pharmacokinetic exposure of antibiotics [5, 6].
These suggestions are based, in part, on numerous data demon-
strating grossly altered pharmacokinetics in critically ill patients
from small single-center studies [7]. Given that antibiotic dos-
ing regimens are derived from healthy volunteers and do not
account for these major differences in drug disposition, the pre-
sent approach is likely to lead to suboptimal outcomes for crit-
ically ill patients [5, 8].
The β-lactams (penicillins, cephalosporins, carbapenems,
and monobactams) are the most commonly prescribed family
of antibiotics. From a pharmacokinetic/pharmacodynamic
(PK/PD) perspective, preclinical studies have deﬁned these an-
tibiotics to be time dependent, that is, the time for which the
free (unbound) antibiotic concentration is maintained above
the minimum inhibitory concentration (MIC) is the determi-
nate factor associated with bacterial killing ( f T>MIC) [9, 10].
Whereas animal in vivo studies have deﬁned an f T>MIC between
40% and 70% of the dosing interval as being necessary [11], ret-
rospective clinical evaluations have suggested that larger drug
exposures are required, with β-lactam concentrations up to 4
times the MIC for the entire dosing interval being suggested
[12, 13]. However, it remains unclear what PK/PD exposure is
clinically necessary for maximal patient beneﬁt.
With the present level of knowledge, there are few robust data
to direct further improvement for antibiotic treatment in criti-
cally ill patients. Limiting progress is the absence of large-scale
data on the appropriateness of present dosing. To address these
deﬁciencies, we undertook the DALI (Deﬁning Antibiotic Lev-
els in Intensive Care Patients) study.
The primary objective of the study was to determine whether
contemporary β-lactam antibiotic dosing in critically ill patients
across a large number of ICUs achieves concentrations associ-
ated with maximal activity. The secondary objective was to cor-
relate the observed antibiotic PK/PD with the clinical outcomes
of therapy.
METHODS
The DALI study was a prospective, multicenter pharmacokinet-
ic point-prevalence study. The detailed protocol for this study
has been published previously [14]. The β-lactam antibiotics el-
igible for this analysis were amoxicillin (coadministered with
clavulanate), ampicillin, cefazolin, cefepime, ceftriaxone, dori-
penem, meropenem, and piperacillin (coadministered with
tazobactam).
Ethical approval to participate in this study was obtained at
all participating centers and informed consent was obtained for
each patient. The lead site was the University of Queensland,
Australia (approval number 201100283, May 2011). Patients
were all identiﬁed for participation by clinical ICU staff on
the Monday of the nominated sampling week, with blood sam-
pling and data collection occurring throughout that week.
PK/PD Targets
The PK/PD ratio is deﬁned as the ratio between the measured
free antibiotic concentration in plasma at 50% or 100% of the
dosing interval and the MIC. The target PK/PD ratios used in
this study are shown in Table 1. Where available, the MIC of the
known pathogen was provided by the local microbiology labo-
ratory. Where an MIC was not available, as many centers do
not routinely generate these data, the MIC of the pathogen
was deﬁned by the European Committee on Antimicrobial Sus-
ceptibility Testing’s MIC90 data (http://www.eucast.org/
clinical_breakpoints). Where no pathogen was formally identi-
ﬁed, the highest MIC for susceptible bacteria to the antibiotic
was assumed. These breakpoints were chosen for a worst-case
scenario of bacterial susceptibility, which is what empiric dosing
is based upon.
Table 1. Deﬁnitions Used for Pharmacokinetic/Pharmacodynamic
and Clinical Endpoints
PK/PD Target Description
50% f T>MIC Free drug concentration maintained above MIC
of the known or suspected pathogen for at
least 50% of dosing interval. This was
considered to be the most conservative PK/PD
target.
50% f T>4×MIC Free drug concentration maintained above a
concentration 4-fold higher than the MIC of the
known or suspected pathogen for at least 50%
of dosing interval.
100% f T>MIC Free drug concentration maintained above MIC
of the known or suspected pathogen
throughout the entire dosing interval.
100% f T>4×MIC Free drug concentration maintained above a
concentration 4-fold higher than the MIC of the
known or suspected pathogen throughout the
entire dosing interval.
Positive clinical
outcome
Completion of treatment course without change
or addition of antibiotic therapy, and with no
additional antibiotics commenced with 48 h of
cessation. De-escalation to a narrower
spectrum antibiotic was permitted but
excluded from the clinical outcome analysis.
Negative clinical
outcome
Any clinical outcome other than positive clinical
outcome.
Abbreviations: MIC, minimum inhibitory concentration; PK/PD, pharmacokinetic/
pharmacodynamic.
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Study Treatments and Blood Sampling
Antibiotic dosing was done as per the treating clinician and
therapy could be administered by either intravenous inter-
mittent or continuous infusion. Each patient had 2 blood sam-
ples taken for each β-lactam antibiotic he or she was receiving.
Blood sample A was a mid-dose blood sample at 50% of the
way through a dosing interval and blood sample B was a pre-
dose level at the end of a dosing interval. The observed con-
centrations were then interpreted in relation to the known or
presumed MIC of the pathogen. For example, the 100%
f T>4×MIC would be attained if the blood sample B concentration
exceeded the MIC by at least a factor of 4.
Data Collection
Data collection was performed by trained staff at each participating
center and entered onto a case report form. Various demographic
and clinical data were collected including age, sex, height, weight,
presence of renal replacement therapy, and measures of organ
function and levels of patient sickness severity as described by
the APACHE II (Acute Physiology and Chronic Health Evaluation
II) score [15] on admission and SOFA (Sequential Organ Failure
Assessment) score on day of sampling [16]. Mortality at 30 days
was also collected. Clinical outcome of therapy was assessed
using the deﬁnitions in Table 1. Combination therapy was deﬁned
as the concomitant use of ≥2 antibiotics of different mechanistic
classes at the time of pharmacokinetic sampling.
Antibiotic dosing data including the dose, infusion duration,
frequency of administration, the time of dosing and sampling,
and the day of antibiotic therapy were collected. All data were
collated by the coordinating center (Burns Trauma and Critical
Care Research Centre, University of Queensland, Australia).
Maintenance of Sample Integrity
Blood samples were processed and stored per protocol to main-
tain integrity. A commercial courier company transported the
clinical samples on dry ice to the coordinating center.
Bioanalysis
The concentration of the study antibiotics in the biological
samples were determined by validated chromatographic
methods (high performance liquid chromatography and liquid
chromatography with tandem mass spectrometry) (US Food
and Drug Administration guidelines: www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guidances/
UCM070107.pdf ). Unbound drug concentrations were directly
measured for the highly protein-bound drugs cefazolin and cef-
triaxone using ultraﬁltration with 30 kDa cutoff devices (Cen-
trifree, Merck Millipore, Tullagreen, Ireland) [17].
Statistical Analysis
Basic statistics on demographic, clinical, and PK/PD-related
data were presented by number (%) or median (interquartile
range [IQR]), as appropriate. The distributions of clinical and
PK/PD-related study parameters were compared among differ-
ent antibiotics using the Kruskal-Wallis test.
To evaluate and compare the possible association of PK/PD
targets with therapy-related outcome, after adjusting for
APACHE II and SOFA scores, the skewed logistic regression
technique was used [18]. The odds ratios (ORs) and boot-
strapped 95% conﬁdence intervals (CIs) were obtained, and
the model ﬁts were assessed using Akaike information criteria
and Bayesian information criteria. Based on the estimated prob-
abilities from the above models, the area under the receiver op-
erating characteristic curve (AUROC) with 95% CIs was
estimated.
The probability of a positive clinical outcome associated with
the ratio of concentration to MIC in interaction with higher and
lower levels of sickness severity (APACHE II score) were evalu-
ated using an interaction-based logistic regression setup. High
and low sickness severity groups were categorized into ﬁrst
and third quartiles. Graphical presentation of the conﬁdence
bounds for the probability of positive clinical outcome associat-
ed with concentration to MIC ratio were developed using these
groups.
RESULTS
Demographic and Clinical Data
In 68 ICUs across 10 countries, 384 patients receiving β-lactam
antibiotics were identiﬁed. Twenty-three patients were excluded
because of protocol violations relating to incorrect blood sample
timing, leaving 361 evaluable patients. The demographic and
clinical details for the patients are described in Table 2.
Table 2. Clinical and Demographic Characteristics of Included
Patients
Characteristic
All Patients
(n = 361)
Patients Treated for
Infection (n = 248)
Male sex, % 65 65
Age, y 61 (48–73) 60 (48–74)
Weight, kg 75 (65–85) 78 (65–86)
APACHE II score 18 (13–24) 18 (14–24)
SOFA score 5 (2–9) 6 (3–9)
Serum creatinine
concentration, µmol/L
77 (53–134) 76 (53–144)
Calculated creatinine
clearance, mL/min
80 (42–125) 82 (44–125)
Urinary creatinine clearance,
mL/min
62 (31–107) 64 (32–103)
Data are presented as median (interquartile range) unless otherwise specified.
Abbreviations: APACHE, Acute Physiology and Chronic Health Evaluation;
SOFA, Sequential Organ Failure Assessment.
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Antibiotics were mostly used for treatment of infection
(68.7%), with the remainder deﬁned as therapy for prophylaxis
of infection (31.3%). One-third of patients (32.6%) had their
antibiotic course commenced in the 24 hours prior to blood
sampling.
PK/PD Data
The data describing the achievement of PK/PD targets with em-
piric dosing are described in Table 3. The box-and-whisker
plots in Figure 1 show up to 500-fold variations in the unbound
concentrations of some antibiotics at both the 50% and 100%
sampling times. As shown by the boxplots in Figure 2, this con-
centration variation also extended to variation of PK/PD indices
at both time points.
Clinical Outcome Data
The clinical cure (positive clinical outcome) rate across patients
receiving both treatment and prophylaxis with β-lactam antibi-
otics was 66.5%. The most common indications for β-lactam
therapy were lung infection (41%) and intra-abdominal infec-
tions (14%). By day 30 following study enrollment, 21.9% of
patients had died; 40.8% of these deaths were considered to
be related to the infection. The total infection-related mortality
for all patients was 8.9%.
Among those treated for infection (n = 248), 144 (58.1%) pa-
tients had a positive clinical outcome. Of the patients treated for
infection, 72.9% had a bacterial pathogen isolated, of which
34.2% had a pathogen MIC available. Of the pathogens identi-
ﬁed, 18% were Pseudomonas aeruginosa (median MIC, 8 mg/L
[IQR, 2–16]) and 16% were Escherichia coli (median MIC, 4
mg/L [IQR 1–16]). The rates of positive clinical outcomes for
these groups were 66% where no pathogen was isolated, 57%
where 1 pathogen was isolated, and 54% for polymicrobial in-
fections. β-Lactam monotherapy treatment was used in 38% of
patients (n = 67), of whom 50% of patients achieved a positive
clinical outcome (compared with the 63% in the combination
therapy group).
Sixty-seven percent of patients being treated for infection re-
ceived therapy by intermittent bolus dosing and 33% by pro-
longed infusion (either an extended infusion ≥2 hours or a
continuous infusion). Of the patients who received prolonged
infusion, 7% did not achieve 50% f T>MIC compared with 20%
of patients receiving intermittent infusion.
Sixteen percent of patients treated for infection did not
achieve 50% f T>MIC, and these patients were 32% less likely
to have a positive clinical outcome (OR, 0.68 [95%
CI,.52–.91]; P = .009).
In our multivariate regression models, only APACHE II
score, SOFA score, and the PK/PD indices 50% f T>MIC and
100% f T>MIC were signiﬁcantly associated with the clinical out-
come (P < .05). The median APACHE II score for patients with Ta
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positive and negative clinical outcomes was 18 (IQR, 13–23)
and 21 (IQR, 16–27), respectively (P < .01). An increase in
APACHE II score by 1 point was signiﬁcantly associated with
a 5% increased risk of negative outcome (OR, 1.05 [95% CI,
1.02–1.07]). For the 50% f T>MIC and 100% f T>MIC data, a high-
er PK/PD ratio was associated with higher likelihood of a pos-
itive clinical outcome (OR, 1.02 [95% CI, 1.01–1.04] and OR,
1.56 [95% CI, 1.15–2.13], respectively). The results for the
model for the 220 patients who did not receive renal replace-
ment therapy are shown in Table 4.
The predictive value of the 50% f T>MIC and 100% f T>MIC
ratio for positive clinical outcome was the same (AUROC,
0.63 [95% CI, .56–.71] and 0.63 [95% CI, .56–.71]) for 50%
f T>MIC and 100% f T>MIC, respectively.
The analyses of interaction effects of sickness severity status and
increasing 50% f T>MIC ratios on the clinical outcome revealed
that the likelihood of positive clinical outcome is signiﬁcantly
higher with increasing level of ratio of antibiotic concentration
to MIC for those with lower APACHE II score, compared to
those with higher APACHE II score (Figure 3A and 3B).
We also examined the effect of 50% f T>MIC on positive clin-
ical outcome for different types of infection. For bloodstream
infections (n = 24), a signiﬁcant association was clearly present
with increasing antibiotic concentrations at 50% of the dosing
Figure 1. The boxplot of antibiotic concentrations observed at 50% (A) and 100% (B) of the dosing interval. Median, interquartile range, and range are
presented. The y-axes are presented on a log2 scale.
Figure 2. The pharmacokinetic/pharmacodynamic (PK/PD) ratios observed at 50% (A) and 100% (B) of the dosing interval. A ratio of 1 is considered to be
a minimum PK/PD target of therapy at 50% of the dosing interval. Note that the PK/PD ratio is deﬁned as the ratio between the measured antibiotic
concentration in plasma at 50% or 100% of the dosing interval and the patient’s minimum inhibitory concentration (MIC) or surrogate when MIC or pathogen
is unknown. Abbreviation: f T>MIC, time the free (unbound) antibiotic concentration was maintained above the minimum inhibitory concentration.
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interval, resulting in a greater probability of positive clinical
outcome (OR, 1.13 [95% CI, 1.07–1.19]). However, neither
lung infection (n = 104; OR, 0.99 [95% CI,.99–1.00]) nor
intra-abdominal infection (n = 35; OR, 1.01 [95% CI,.96–
1.06]) showed any signiﬁcant associations.
The mean and median levels of MIC for all suspected bacteria
in all patients were 8 mg/L and 2 mg/L, respectively. The pa-
tients with a pathogen with a MIC ≤2 mg/L were 2.3 times
more likely to achieve a positive clinical outcome (OR, 2.27
[95% CI, 1.79–2.87]).
DISCUSSION
This multinational point prevalence study is the ﬁrst to examine
unbound plasma concentrations of β-lactam antibiotics and
patient outcome across a large number of ICUs. These data
show that mid-dose and trough β-lactam concentrations vary
widely, and as such, achievement of PK/PD targets is highly incon-
sistent. Of great concern, one-ﬁfth of patients do not even achieve
a minimum conservative PK/PD target, 50% f T>MIC. This study
has also generated interesting hypotheses related to much higher
target β-lactam pharmacokinetic exposures than would have been
previously considered for clinical outcome of infection. The dic-
tum of “one dose ﬁts all” is shown here to be problematic.
Our ﬁnding of large variations in plasma concentrations of
β-lactam antibiotics in ICUs is in keeping with other studies.
Recent reviews have noted the enormous pharmacokinetic var-
iability of β-lactam antibiotics in critically ill patients [6, 7];
however, all the studies commented on in these reviews were de-
rived from single centers or from only very few related centers.
Table 4. Multivariate Regression Results of Clinical Outcome for Patients Who Did Not Receive Renal Replacement Therapy
Model Parameters
50% f T>MIC 100% f T>MIC
OR 95% CI P Value OR 95% CI P Value
APACHE II score 0.94 .92–.96 <.001 0.94 .92–.96 .97
SOFA score 0.97 .94–1.00 .053 0.97 .94–1.01 .13
50% f T>MIC 1.03 1.01–1.04 .001 . . .
100% f T>MIC . . . 1.02 1.01–1.05 .040
AIC 1758.60
BIC 1785.07
Data are presented as estimates of odds ratios (95% CI) and P values. Abbreviations: AIC, Akaike information criteria; APACHE, Acute Physiology and Chronic Health
Evaluation II; BIC, Bayesian information criteria; CI, confidence interval; f T>MIC , time the free (unbound) antibiotic concentration wasmaintained above theminimum
inhibitory concentration; OR, odds ratio; SOFA, Sequential Organ Failure Assessment.
Figure 3. A, The effect of an increasing pharmacokinetic/pharmacodynamic (PK/PD) ratio at 50% of the dosing interval (ratio A) in interaction with Acute
Physiology and Chronic Health Evaluation II (APACHE II) score on the probability of positive clinical outcome (n = 248; y-axis). B, The effect of PK/PD ratio at
50% of the dosing interval (ratio A) in interaction with APACHE II score on the probability of positive clinical outcome for patients not receiving renal
replacement therapy (n = 220; y-axis). The estimated probabilities of positive clinical outcome along with its 95% conﬁdence interval are presented for
the less critically ill patient group (APACHE II score within lowest quartile of 0–14 points; solid black lines) as well as the more critically ill patient group
(APACHE II score within the third quartile of 18–24 points; dashed line). Abbreviations: CI, conﬁdence interval; MIC, minimum inhibitory concentration.
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These studies are valuable because they demonstrate how anti-
biotic concentrations in different types of patients will differ
from non–critically ill patients. Such data are essential for artic-
ulating how antibiotic dosing regimens that meet the speciﬁc
needs of these patients could be developed given that present
regimens are not tested in these most severely ill patients by
pharmaceutical companies.
Antibiotics discovered and evaluated in vitro are tested in an-
imals initially for toxicity, and subsequently for efﬁcacy. The an-
tibiotic dose and frequency are based on these in vitro or animal
in vivo PK/PD studies. These dosing regimens are then tested
on healthy human volunteers for tolerability, with clinical efﬁ-
cacy studies undertaken in non–critically ill patients. After the
launch of the drug onto the general market, the same dosing
regimen is used in critically ill patients; however, this is likely
to lead to suboptimal outcomes in the ICU. Critically ill patients
have altered volumes of distribution for antibiotics [19, 20], and,
unlike other patient groups, need larger initial doses to rapidly
achieve therapeutic concentrations [21]. These patients may
have augmented renal clearances needing either higher doses
or more frequent dosing to overcome increased drug elimina-
tion [22, 23]. Critically ill patients often have low plasma albu-
min concentrations [24] that alters the protein binding of drugs
and has signiﬁcant effects on pharmacokinetics [25, 26].
Given such potential for variability, it is not surprising that
we found that one-ﬁfth of patients did not achieve the most
conservative PK/PD target and <50% of patients achieved
what we a priori deﬁned as a preferred PK/PD target (Table 3).
Furthermore, the variability of unbound concentrations across
all antibiotics (Figure 1) as well as PK/PD ratios (Figure 2) were
similarly large.
The consequences of insufﬁcient antibiotic exposure may be
severe, with clear relationships being demonstrated between an-
tibiotic underdosing and the development of antibiotic resis-
tance [27]. This link was initially shown with inappropriately
low quinolone exposures [28], but more recently with other
classes of antibiotics including β-lactams [29, 30]. ICUs are
known to harbor multidrug-resistant pathogens and, although
there are many reasons for this, optimized dosing that minimiz-
es the evolution of such pathogens should be considered a
method to improve patient and health system outcomes.
The secondary objective of this study was to compare antibi-
otic PK/PD with observed clinical outcomes. An interesting
ﬁnding in our study is the observed signiﬁcant interaction effect
of varying sickness severity while evaluating the dose-response
relationship. The patterns of probability of positive clinical out-
come associated with increasing level of PK/PD ratio were
markedly different for higher and lower levels of disease severity
levels (Figure 3). This novel analysis approach delineates the ef-
fect of antibiotic exposure more accurately. We found that the
magnitude of the β-lactam exposures necessary to achieve a
positive clinical outcome is particularly noteworthy and gener-
ates interesting research questions for future study.
The results of the DALI study support the conclusions of pre-
vious small studies that better outcomes for critically ill patients
can be expected with higher drug exposures, at least for less se-
verely ill patients [12, 13]. These data now support the conduct
of an interventional study comparing critically ill patient out-
comes with different PK/PD targets to deﬁnitively determine
what antibiotic exposures should be targeted in these patients.
This study has notable limitations. While it is a prospectively
designed point prevalence study, it is merely a snapshot picture
of β-lactam antibiotic concentrations in critically ill patients on
a single day [14]. Although we collected data on concomitant
antibiotics, we did not assess the PK/PD of those antibiotics,
nor did we assess duration of therapy of combination or mono-
therapy. Furthermore, pathogens were only grown in 73% of pa-
tients, and the actual MIC was only available in 34% of these
patients, meaning that assumptions were necessary for the re-
maining patients. Such assumptions were of a worst-case sce-
nario, which we believe is highly acceptable as this is the
context governing empiric dose selection. If the infections
were mediated by more susceptible bacteria than were assumed,
the PK/PD ratios would actually have been higher than those we
described here. Finally, we have not speciﬁcally looked at drug
concentrations at the site of infection, because of the technical
challenges in performing such a large-scale evaluation. Howev-
er, our data interestingly show that for bloodstream infections,
where antibiotic concentrations were measured, a strong PK/PD
relationship was present.
CONCLUSIONS
The implications of this large study performed across 68 ICUs are
profound. These data show that many patients fall below PK/PD
targets (less than the most conservative PK/PD target in 20% of
patients, and less than our suggested target in 50%). The results
suggest that ICU clinicians should reﬁne dosing strategies for crit-
ically ill patients to optimize β-lactam antibiotic outcomes. With
the signiﬁcant pharmacokinetic variability observed, a more per-
sonalized approach to antibiotic dosing would need to be adopt-
ed to ensure that target drug exposures are assured.
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